accountFollowing similar deals by Switzerland's Novartis AG and Japan's biggest drug company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson (NYSE: JNJ) is acquiring Cougar Biotechnology Inc. (NASDAQ: CGRB), a development stage biopharmaceutical company with a specific focus on oncology for about $970 million in cash.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to J&J follows trend, buys into oncology for $1B
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account